AMDL Announces Sales of $5.8 Million for Third Quarter 2007 Results
Mr. Gary Dreher, CEO of AMDL, noted that, "AMDL's introduction of newproducts and increased distribution channels caused the upturn in revenuesdemonstrates that JPI should continue to provide earnings in the future. Weanticipate that our Chinese subsidiaries will continue to experience strongsales and gross profit growth that will greatly improve AMDL's combinedoperating results."
About AMDL: More information about AMDL and its products can be obtainedat http://www.amdl.com. AMDL, together with Jade, engages in the development,manufacture and marketing of proprietary pharmaceutical and diagnosticproducts.
About Jade: Jade has access to the fastest growing pharmaceutical andconsumer market in the world: China. AMDL, through its Jade subsidiaries,currently holds licenses for 133 products that are manufactured as largevolume injection fluids, tablets and other related products. It currentlymanufactures over 20 key generic, over the counter and supplementalpharmaceutical products under certified Chinese Good Manufacturing Practice(CGMP) standards.
Forward-Looking Statements: This news release contains forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995. Such statements are subject to certain risks and uncertainties, andactual circumstances, events or results may differ materially from thoseprojected in such forward-looking statements. The Company cautions readers notto place undue reliance on any forward-looking statements. The Company doesnot undertake, and specifically disclaims any obligation, to update or revisesuch statements to reflect new circumstances or unanticipated events as theyoccur.Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460 For Immediate Release
SOURCE AMDL, Inc.
You May Also Like